FDA approves two new treatment regimens:
1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT
2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)
